Feldene's first full year sales
Pfizer's one-a-day nonsteroidal anti-inflammatory had U.S. retail sales of $124 mil. (at acquisition cost) in its first 12 months on the market, according to Pharmaceutical Data Services' (PDS) data. PDS' first year retail sales projection for Glaxo's Zantac in the U.S. was $110 mil., putting Feldene ahead of the anti-ulcer agent in first year sales performance. Based on information from another source, "The Pink Sheet" put Feldene first year sales at $109 mil. (July 30, T&G-1).
You may also be interested in...
The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.
Given inconsistent study results, robustness of the efficacy evidence is expected to be key focus of the 6 November meeting of the Peripheral and Central Nervous System Drugs Advisory Committee; review could put a December 2019 guidance on the ‘substantial evidence’ standard to the test and offer insight into the amount of flexibility the agency is willing to exercise for neurodegenerative diseases with high unmet need.
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.